trending Market Intelligence /marketintelligence/en/news-insights/trending/Ltn5pkS3Bt71DU6mph18Zw2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

VolitionRx acquires epigenetic reagent developer Octamer in €650,000 deal

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


VolitionRx acquires epigenetic reagent developer Octamer in €650,000 deal

VolitionRx Ltd. agreed to acquire Munich-based epigenetic reagent developer Octamer GmbH in a €650,000 cash and share deal.

Singapore-based cancer diagnostic test developer VolitionRx — operating through its unit Belgian Volition SA — is offering 73,000 common shares of Volition and €350,000 cash in exchange for all outstanding shares of Octamer.

The acquisition, expected to close in January 2020, will help secure the supply of the recombinant nucleosome, which is used as a calibrant for Volition's cancer diagnostic test Nu.Q.